ImmunityBio Inc (NASDAQ: IBRX) says it will make its first COVID-19 vaccine in South Africa by The Biovac Institute, a partly state-owned company, once regulators approve it, reports Bloomberg.

• Production of ImmunityBio’s vaccine in South Africa will bolster its role as the only country in Africa to produce the shots. Aspen Pharmacare Holdings Ltd. will start making Johnson & Johnson’s (NYSE: JNJ) single-shot doses in the second quarter of this year at a facility in Gqeberha.

• ImmunityBio’s vaccine is in Phase 1 trials and uses a cold germ, known as adenovirus 5, to act against the coronavirus.

• Its so-called hAd5 T-cell kills infected cells, and in addition to the spike proteins found on the coronavirus, the shot targets the nucleocapsid protein, which is less prone to mutations.

• Earlier this week, the company met the safety requirements for the first 12 participants in its Phase 1b COVID-19 vaccine trials in sublingual and oral formulations.

• The independent Safety Review Committee recommended the study continue with no modifications to the trial design. Enrollment will complete in the second quarter.

• Price Action: IBRX shares closed 4.4% lower at $34.36 on Thursday.

See more from Benzinga

• Click here for options trades from Benzinga

• Incyte's Ruxolitinib Fails To Beat Placebo In Improving Mortality In Critically-Ill COVID-19 Patients

• EMA 'Firmly Convinced' With Benefits Of AstraZeneca Vaccine Exceeding Risks: Report

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.